• Sign In
  • Register
  • Glossary
  • Share/Bookmark
  • RSS
All About Bleeding

Clinical Studies

Novel Recombinant Hemophilia Treatments

CSL Behring’s recombinant factor development pipeline is built on its strength in protein research and development and scientific expertise in bleeding disorders

Learn more

Research Efforts

CSL Behring is committed to the future research and development of coagulation therapies.

Learn More

The following list includes current CSL Behring studies. Please visit ClinicalTrials.gov for details about each clinical trial.

AFFINITY      AFFINITY Clinical Trials Information

Hemophilia A

  • Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A (AFFINITY CSL627_3002) ClinicalTrials.gov study record detail
  • An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A (AFFINITY CSL627_3001) ClinicalTrials.gov study record detail
  • An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A (AFFINITY CSL627_1001) ClinicalTrials.gov study record detail
PROLONG-9FP       PROLONG-9FP Clinical Trials Information

Hemophilia B

  • A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B (PROLONG-9FP CSL654_3002) ClinicalTrials.gov study record detail
  • A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B (PROLONG-9FP CSL654_3003) ClinicalTrials.gov study record detail

 

 

 


Last Updated: 7/6/2016 8:26 AM
  • E-mail
  • Print
  • Share